UiO - Det medisinske fakultet

Stor bevilgning til forskning på ny banebrytende teknologi

Del
European Innovation Councils Pathfinder Challenges-program har bevilget 4,95 millioner EUR til det internasjonale forskningskonsortiet "Supervised Morphogenesis in Gastroloids" (SUMO). Med bruk av gastruloidteknologi for dannelse av multivevs embryonale organoider, ønsker SUMO-konsortiet å løse utfordringer knyttet til fremstilling av realistiske organmodell-systemer.
Stefan Krauss, leder for Senter for biohybridteknologi ved UiO
Stefan Krauss, leder for Senter for biohybridteknologi ved UiO

The interdisciplinary consortium “Supervised Morphogenesis in Gastruloids” (SUMO) received a total funding of 4.95 mio EURO from the Pathfinder program of the European Innovation Council (EIC) to challenge the current limitations for realistic in vitro organ models by building on state-of-the-art gastruloid technology.

Gastruloids are multi-tissue embryonic organoids that can recapitulate mammalian developmental processes, including early organogenesis, in a dish. They harbor great promise for both fundamental and applied science for their ability to model organ primordia in the framework of their native three-dimensional context.

To fully harness the potential of gastruloid technology, the SUMO consortium will tackle current bottlenecks regarding gastruloid reproducibility, tissue organization and physiology using cutting edge technology including Raman imaging, artificial intelligence and bioengineering. Specifically, the consortium aims to achieve reproducible and scalable formation of gastruloids with embryo-like morphology that enter advanced organogenesis stages, focusing on cardiac and gut development.

The SUMO consortium unites researchers from the University Hospital Oslo and the University of Oslo, Norway (Stefan Krauss, coordinator), Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) (Jesse Veenvliet), Imperial College London, UK (Molly Stevens), University of Glasgow, UK (Nikolaj Gadegaard), Tel Aviv University, Israel (Iftach Nachman), Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Germany (Jens von Kries) and University of Oslo (Jan Helge Solbakk).

The SUMO consortium enters a portfolio of seven consortia that are funded within the “Engineered Living Materials” EIC challenge.

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth said, “Congratulations to all projects selected under the first EIC Pathfinder Challenges call. With the support of EIC Program Managers, they will progress together towards common goals and create new opportunities for radical innovation. With the new mechanisms under the EIC, we have the means to support the whole value chain and to transform these innovative technologies into successful companies in Europe.” 

Nøkkelord

Kontakter

Bilder

Stefan Krauss, leder for Senter for biohybridteknologi ved UiO
Stefan Krauss, leder for Senter for biohybridteknologi ved UiO
Last ned bilde

Om UiO - Det medisinske fakultet

UiO - Det medisinske fakultet
UiO - Det medisinske fakultet
Klaus Torgårds vei 3
0372 Oslo

22 84 53 00http://www.med.uio.no

Les mer om Senter for biohybridteknologi ved UiO: https://www.med.uio.no/hth/

Følg pressemeldinger fra UiO - Det medisinske fakultet

Registrer deg med din e-postadresse under for å få de nyeste sakene fra UiO - Det medisinske fakultet på e-post fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra UiO - Det medisinske fakultet

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom
HiddenA line styled icon from Orion Icon Library.Eye